Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by
diffused inflammation of the colon and rectum mucosa; however, the exact underlying
mechanisms of UC remain poorly understood. Also, it is associated with high risk of colon
cancer, so there is a continuous need for introducing new therapies that decrease
progression, and hence better outcomes